NCT02306837

Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies

A Phase II Trial of Consolidation Chemothetapy for Patients With Relapse or Refractory Lymphoid Malignancies After Autologous Stem Cell Transplantation

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: 16 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

To imporve the outcome of patients with relapsed/refractory lymphoma, we conduct a clinical trial to test the efficacy and feasibility of consolidation chemotherapy after autologous stem cell transplantation

Detailed description

Patients with relapsed or refractory lymphoma will be included. All patients will undergo PBSC mobilization with CTX and G-CSF. After sucessful collection of CD34+ over 1x109/L, autologous stem cel ltransplantation with Bu-Cy-E conditioning will be given. Two months after auto-HSCT, a PET-CT will be performed and all patients with CR, CRu and PR will recieved 3 cycles of mini-Bu-Cy-E as consolidation 3, 6 and 9 months after auto-HSCT. For patients with SD or PD after auto-HSCT will refered to the allogeneic transplantatio program and take off the study.

Conditions

• Effects of Chemotherapy

Interventions

Type	Name	Description
DRUG	Bu-CY-E	mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT

Timeline

• Start date: 2014-09-01
• Primary completion: 2018-09-01
• Completion: 2019-09-01
• First posted: 2014-12-03
• Last updated: 2016-09-08

Locations

2 sites across 1 country: China